Propranolol Rewires Burn Injury Metabolism

2026-08-17

This phase II randomized controlled trial links propranolol treatment after severe burn injury to coordinated changes in adipose-tissue metabolomics, lipidomics, hormone-sensitive lipase activity, and endoplasmic reticulum stress. The findings provide a mechanistic framework for understanding how β-adrenergic blockade may reduce postburn hypermetabolism and shift inflammatory lipid signaling.

β-Elemene Inhibits Adipogenesis via AMPK in 3T3-L1 Cells

2026-08-16

The reference study identifies β-Elemene as an inhibitor of MDI-induced adipogenesis in 3T3-L1 preadipocytes and links this effect to restoration of AMPK pathway activity. Its value is primarily mechanistic: the work connects lipid accumulation, insulin resistance-related glucose handling, and AMPK signaling in a defined cellular model while also clarifying the limits of extrapolating these findings to obesity treatment.

CCCP: Mitochondrial Proton Gradient Disruption

2026-08-15

CCCP, or carbonyl cyanide m-chlorophenyl hydrazine, is a research uncoupler that dissipates the mitochondrial proton motive force and inhibits oxidative phosphorylation. It is useful for controlled in vitro mitochondrial perturbation, but it is not an Alzheimer’s disease biomarker, treatment, or clinical reagent.

Uridine, Trisodium Salt in Cell Assays

2026-08-14

Learn how Uridine, Trisodium Salt (SKU B1473) can be incorporated into controlled RNA metabolism, proliferation, cytotoxicity, and vascular research workflows. This scenario-based guide emphasizes solubility, storage, assay controls, interpretation, and evidence-aware vendor selection.

Trichostatin A (TSA): HDAC Inhibitor Guide

2026-08-14

Trichostatin A (TSA) is a reversible HDAC inhibitor used to study histone acetylation, cell-cycle control, differentiation, and cancer biology. Product data report breast cancer cell-growth inhibition at an approximate IC50 of 124.4 nM, while a separate cardiomyocyte study provides chromatin-context evidence rather than direct evidence of TSA efficacy.

How Near-Death Tumor Cells Seed Metastasis

2026-08-13

Conod, Silvano, and Ruiz i Altaba identify impending cell death as an active source of prometastatic tumor states rather than merely a mechanism of tumor-cell elimination. Their work defines PAMEs, links their formation to ER stress and nuclear reprogramming, and shows how cytokine-mediated recruitment of neighboring PIMs creates a metastasis-supportive ecosystem.

REV1–DHX36 Coordination of G-Quadruplex Tolerance

2026-08-13

A 2026 Nucleic Acids Research study identifies a direct REV1–DHX36 interaction that coordinates G-quadruplex unwinding, replication-fork progression, and suppression of single-stranded DNA gaps. The findings define a two-tier mechanism for G4 tolerance and connect REV1 deficiency with increased ATM/ATR signaling and sensitivity to G4-stabilizing agents.

SERCA2 Dysfunction, ROS, and Pulmonary Remodeling

2026-08-12

The reference study identifies SERCA2 dysfunction as an upstream driver of pulmonary vascular inflammation, oxidative stress, and remodeling through suppression of the PPARγ/PGC1α/Nrf2 axis. Its combination of a SERCA2 C674S mouse model, pulmonary artery smooth muscle cell experiments, and mechanistically directed rescue treatments provides a framework for connecting calcium dysregulation with redox-dependent vascular disease.

Norepinephrine, K⁺ Channels, and Renal Flow in Sepsis

2026-08-12

The reference study examined how norepinephrine and phenylephrine interact with renal vascular potassium channels in septic rats, combining isolated kidney perfusion with in vivo renal blood-flow measurements. Its central finding is that pharmacological blockade of Kir6.1-containing ATP-sensitive or KCa1.1 calcium-activated potassium channels can worsen catecholamine-associated renal hypoperfusion, emphasizing that systemic vasopressor responses may not predict kidney-specific effects.

OM-MSCs Protect Golgi Function After Cerebral IRI

2026-08-11

The reference study identifies a mechanistic link between olfactory mucosa mesenchymal stem cells, PEDF secretion, and Golgi apparatus stress after cerebral ischemia/reperfusion injury. Using OGD/R and reversible MCAO models, it shows that OM-MSCs reduce GOLPH3-associated stress, oxidative and calcium disturbances, Golgi fragmentation, and excessive autophagy through PI3K/Akt/mTOR pathway activation.

CAY10499 in Translational Immunometabolism

2026-08-11

CAY10499 offers a practical way to interrogate HSL- and MGL-dependent lipid flux alongside the ACLY-driven metabolic reprogramming recently linked to tumor-associated macrophages in hepatocellular carcinoma. This thought-leadership perspective translates those findings into assay strategy while distinguishing mechanistic opportunity from evidence that remains preliminary.

JNJ-26481585 (Quisinostat) Workflow Guide

2026-08-10

Build more informative HDAC inhibition experiments with JNJ-26481585 (Quisinostat), from concentration-response screening to apoptosis, histone acetylation, and resistance assays. The workflow connects broad anti-proliferative activity with the TRIM21–ERK1/2 findings reported in pituitary adenoma models.

Removing Pollen Interference in Bioaerosol EEM

2026-08-09

Haptotactic Motion of Multivalent Vesicles

2026-08-08

Sleath and colleagues developed a synthetic giant unilamellar vesicle system to test how multivalent adhesion drives passive motion along ligand-density gradients. Their combined experiments, numerical modeling, and theory show that directional migration depends on both molecular binding strength and vesicle size, providing design principles for biomimetic motile systems.

Asunaprevir: From Protease Biology to Assay Design

2026-08-07

Asunaprevir (BMS-650032) is a potent HCV NS3 protease inhibitor with broad genotype activity. This guide develops an assay-first framework linking target engagement, HCV RNA replication inhibition, compound handling, and orthogonal validation without overstating cross-pathway effects.